Poitiers

• Tarlatamab vs standard of care chemotherapy in patients with pre-treated advanced, pulmonary or gastroenteropancreatic poorly differentiated … Recruiting
  2024-515948-23-00 5 2026-02-06 Advanced pulmonary or gastroenteropancreatic poorly differentiated neu
• Randomized Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carc … Recruiting
  2024-515023-11-00 5 2026-01-22 Metastatic Clear Cell Renal Cell Carcinoma
• FILOWM4-WaZaBi: "Open label phase 2 study evaluating the efficacy and tolerance of a zanubrutinib and BGB-11417 combination in patients prev … Recruiting
  2023-505781-28-00 4 2026-01-20 Patients with Waldenstrom macroglobulinemia and have received at least
• Efficacy of intravesical oxybutynin in children with neurogenic bladder dysfunction: A randomized, prospective controlled multi-center trial … Recruiting
  2022-501902-36-00 5 2026-01-15 spina bifida
• GRAALL 2024 - A 3-cohort Randomized Study evaluating the role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Tran … Recruiting
  2024-511437-35-00 10 2026-01-05 Patients aged 18-65 years old with newly diagnosed previously untreate
• ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid … Recruiting
  2025-522395-92-00 5 2025-12-15 metastatic oeso-gastric adenocarcinoma
• Open label phase II study evaluating the efficacy and safety of the combination of tagraxofusp and venetoclax in treatment-naive blastic pla … Recruiting
  2024-511003-42-00 4 2025-12-11 BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASMS
• Dapagliflozine for cardio-renal protection at ICU discharge Recruiting
  2024-510941-32-00 5 2025-12-02 Adult patients discharged alive from ICU with a decreased eGFR, and/or
• Risk-adapted adjuvant chemotherapy guided by the tumour stage for operated pancreatic adenocarcinoma following neoadjuvant chemotherapy with … Recruiting
  2024-519048-33-00 10 2025-11-25 resected pancreatic adenocarcinoma
• A study to evaluate the safety and efficacy of two dose levels of ONO-4578 with Opdivo®, in combination with mFOLFOX6 and bevacizumab versus … Recruiting
  2024-519590-19-00 4 2025-11-25 PD-L1 positive advanced colorectal cancer
• Clinical trial evaluating the activity of zanidatamab for the treatment of patients with solid tumors with an alteration of the HER2 gene Recruiting
  2025-522169-31-00 4 2025-10-30 Adult Patients with HER2-IHC3+ selected solid cancers (endometrial, co
• AKAPI: Amikacin Liposome Inhalation Suspension for treatment of Mycobacterium xenopi pulmonary infection: A prospective controlled open-labe … Recruiting
  2023-506843-40-00 5 2025-10-29 Mycobacterium xenopi pulmonary infection
• Testing ivonescimab in combination with standard chemotherapy in advanced or metastatic gastric and gastroesophageal adenocarcinoma patients Recruiting
  2025-520694-39-00 4 2025-10-24 Metastatic or locally advanced irresectable (stage IV) gastric cancer
• A Phase 1 Study of NDI-219216 in Patients with Advanced Solid Tumors with and without Microsatellite Instability and/or Deficient Mismatch R … Recruiting
  2025-522774-36-00 1 2025-10-24 Advanced solid tumors
• A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antim … Recruiting
  2024-517140-65-00 9 2025-10-23 Multiple Myeloma (MM).
• Durvalumab and tremelimumab with or without Hepatic Arterial Infusion of gemcitabine and oxaliplatin in hepatocellular carcinoma patients. Recruiting
  2024-514912-28-00 10 2025-10-22 Patients with hepatocellular carcinoma with high tumor burden.
• Efficacy of dexmedetomidine versus midazolam sedation on extubation time in mechanically ventilated preterm infants: a randomized controlled … Recruiting
  2023-508785-16-00 5 2025-10-17 Very preterm neonate (gestational age at birth < 32 WG) with corrected
• Phase IIIb Study of 36-Week Refill Exchanges of Port Delivery System with Ranibizumab in nAMD Recruiting
  2024-516924-32-00 5 2025-10-17 Neovascular Age-Related Macular Degeneration (nAMD)
• EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure … Recruiting
  2025-521188-11-00 5 2025-10-15 Type 2 diabetes
• The effect of amantadine as add-on therapy for motor fluctuations in advanced Parkinson’s disease: a randomized double-blinded placebo-contr … Recruiting
  2023-509728-16-00 4 2025-10-10 advanced Parkinson’s disease
• Efficacy and safety of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by o … Recruiting
  2023-509275-17-00 5 2025-10-06 Relapsing multiple sclerosis
• SAFE-ESO_Phase II study evaluating safety and efficacy of Tislelizumab for elderly patients unfit for chemotherapy, with advanced esophageal … Recruiting
  2024-518358-17-00 4 2025-10-06 Squamous cell carcinoma of the esophagus
• Strategies for zoledronic acid post-denosumab discontinuation in postmenopausal osteoporosis Recruiting
  2024-511871-13-00 6 2025-10-02 Postmenopausal osteoporosis
• INTER-EWING-1: International Clinical Research Programme to Improve Outcomes in Newly Diagnosed Ewing Sarcoma – Trial 1 Recruiting
  2024-511989-36-00 5 2025-09-24 Ewing Sarcoma

Showing 121–144 of 605 trials